Skip to main content

Advertisement

Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition

Fig. 3

Dabrafenib and trametinib do not impair maturation of ex vivo cultured pDCs and mDCs. Freshly isolated pDCs (a) and mDCs (b) were cultured ex vivo and activated with R848 in presence or absence of 60 μg/ml vemurafenib, 90 ng/ml dabrafenib and 12 ng/ml trametinib. Graphs show the cell surface expression levels of CD80, CD86, PD-L1, MHC-I and MHC-II after 18 h. Shown is the mean (+SEM) of three independent experiments *P < 0.05, **P < 0.01,***P < 0.001

Back to article page